Indian pharma firms lag behind global peers in RnD, Patents, Publications, reveals report
The largest disparity was observed in the number of publications per billion USD revenue, with global firms producing 8.4 times more publications than India
Written By : Farhat Nasim
Published On 2024-10-21 08:45 GMT | Update On 2024-10-21 08:45 GMT
New Delhi: Indian pharmaceutical companies are lagging behind their global counterparts in critical performance areas, such as R&D intensity, the share of PhD-level employees, and the number of patents and publications produced per billion USD of revenue, as highlighted in a report by the Foundation for Advancing Science and Technology (FAST India) in partnership with IIFL Securities.
The largest disparity was observed in the number of publications per billion USD revenue, with global firms producing 8.4 times more publications than Indian firms, the report noted.
Global firms generated 5.6 times more patents and 8.4 times more publications per billion USD of revenue compared to Indian firms.
In terms of Research and Development (R&D) intensity, global firms outperformed Indian firms by a factor of 3.0, the report added.
The report also highlighted that Indian pharmaceutical companies are performing better in the patents-to-revenue parameter than in the publications-to-revenue parameter, with four Indian firms ranking among the top ten for patents by revenue.
American multinational pharmaceutical company Eli Lilly ranked first overall for R&D intensity and third for the proportion of PhD employees, the report said.
Among Indian firms, Dr. Reddy's Laboratories ranked first in both R&D intensity (10.3 per cent) and the proportion of PhD employees (0.97 per cent).
Bengaluru-based Biocon ranked first among Indian firms for publications per billion USD revenue and third overall. Sun Pharmaceuticals ranked first among Indian firms for patents by revenue and third overall, with 636 patents per billion USD of revenue, surpassing many global and Indian firms, according to the report.
The Indian pharmaceutical sector contributes 1.72 per cent to the country's GDP, with around 3,000 companies and over 10,563 industrial units as of 2021.
FAST India further noted that policy reforms introduced during liberalisation, such as amendments to the Patents Act, the allowance of FDI, and the introduction of Production Linked Incentives (PLIs), have established India as a global leader in drug manufacturing.
India is currently the third-largest drug producer by volume and supplies 20 per cent of the global generic drug market. In the 2022 financial year, Indian pharmaceutical exports, including bulk drugs, intermediates, formulations, and biologicals, amounted to USD 23.5 billion.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.